Company to retain economic interest in biotherapeutic asset while removing cash burn from development and commercialization costsREDWOOD CITY, Calif., Dec.…
NKGen’s SNK01 program continues to show positive progress with the FDA IND clearance in October 2023, and now the CTA…
BRISBANE, Calif., Dec. 27, 2023 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on…
In an acute colitis model, data show statistically significant knockdown of elevated levels of serum TNFα, reductions in tissue TNFα…
CELEBRATION, Fla., Dec. 27, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) a rare disease therapeutics company, today announced…
No dose limiting toxicities were reported in the first cohort of ultra-high concentration of nitric oxide administered at 25,000 parts…
Statistically Significant and Clinically Meaningful Increasein Primary Efficacy Endpoint at 24 Weeks of Treatment; Improvement Consistent Across All Prespecified Subgroups…
SAN CARLOS, Calif., Dec. 27, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating,…
WAYNE, Pa. and ROCKVILLE, Md., Dec. 27, 2023 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) today announced a 1-for-240…
VANCOUVER, British Columbia, Dec. 27, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) (the “Company” or…